|
|
|
| Research progress of relationship the between immune cells and hepatocellular carcinoma |
| ZHAGN Jinghao1 ZHENG Chao1 ZHOU Zhenhua2 ZHU Xiaojun1 ZHANG Xin2 SUN Xuehua1,2 GAO Yueqiu1,2 |
1.Department of Hepatology, Shuguang Hospital Affiliated of Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;
2.Clinical Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai 201203, China |
|
|
|
Abstract Hepatocellular carcinoma (HCC) is the primary malignant tumor of liver, which has a high morbidity and mortality. Dysfunction of the immune system can lead to abnormal immune surveillance of HCC, and hepatocellular carcinoma cells can also act on the immune system to lead immune escape. Immune cells including dendritic cells (DCs), macrophage (MΦ), myeloid-derived suppressor cells (MDSCs), natural killer cell (NK), cytotoxic lymphocyte (CTL), CD4+T cell, regulatory cells (Treg), helper T cell 7 (Th7) and natural killer T cells (NKT), play an important role in the occurrence and development process of HCC. In this paper, advances in the interaction between immune cells and liver cancer are reviewed to provide new ideas and methods for the treatment of HCC.
|
|
|
|
|
|
[1] Forner A，Llovet JM，Bruix J. Hepatocellular carcinoma [J]. Lancet，2012，379（9822）：1245-1255.
[2] El-Serag HB，Marrero JA，Rudolph L，et al. Diagnosis and treatment of hepatocellular carcinoma [J]. Gastroenterology，2008，134（6）：1752-1763.
[3] Aravalli RN，Steer CJ，Cressman EN. Molecular mechanisms of hepatocellular carcinoma [J]. Hepatology，2008，48（6）：2047-2063.
[4] 邵家胜，卢洪洲，张永信.肝细胞癌流行病学研究进展[J].肝脏，2011，16（6）：503-505.
[5] Matsui M，Machida S，Itani-Yohda T，et al. Downregulation of the proteasome subunits，transporter，and antigen presentation in hepatocellular carcinoma，and their restoration by interferon-gamma [J]. J Gastroenterol Hepatol，2002，17（8）：897-907.
[6] Ninomiya T，Akbar SM，Masumoto T，et al. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma [J]. J Hepatol，1999，31（2）：323-331.
[7] Chen S，Akbar SM，Tanimoto K，et al. Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma：relevance to hepatocarcinogenesis [J]. Cancer Lett，2000，148（1）：49-57.
[8] Han Y，Chen Z，Yang Y，et al. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2，3-dioxygenase production in hepatocellular carcinoma [J]. Hepatology，2014，59（2）：567-579.
[9] Yan W，Liu X，Ma H，et al. Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages [J]. Gut，2015，64（10）：1593-1604.
[10] 陈伟，周赟，龚建平.肿瘤相关巨噬细胞在原发性肝癌发生发展中的作用[J].临床肝胆病杂志，2016，32（7）：1422-1424.
[11] Zhu XD，Zhang JB，Zhuang PY，et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma [J]. J Clin Oncol，2008，26（16）：2707-2716.
[12] 王平忠，黎志东，于海涛，等.NK细胞的活化及其介导的抗病毒作用[J].细胞与分子免疫学杂志，2012，28（3）：330-332.
[13] Gao B，Radaeva S，Park O. Liver natural killer and natural killer T cells：immunobiology and emerging roles in liver diseases [J]. J Leukoc Biol，2009，86（3）：513-528.
[14] Muhanna N，Doron S，Wald O，et al. Activation of hepatic stellate cells after phagocytosis of lymphocytes：A novel pathway of fibrogenesis [J]. Hepatology，2008，48（3）：963-977.
[15] 徐岷，蒋健.髓源抑制细胞参与肿瘤免疫逃逸的研究进展[J].医学综述，2015，21（6）：1003-1005.
[16] Gabrilovich DI，Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system [J]. Nat Rev Immunol，2009，9（3）：162-174.
[17] Attallah AM，Tabll AA，El-Sadany M，et al. Dysregulation of blood lymphocyte subsets and natural killer cells in schistosomal liver cirrhosis and hepatocellular carcinoma [J]. Clin Exp Med，2003，3（11）：181-185.
[18] Wu K，Kryczek I，Chen L，et al. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions [J]. Cancer Res，2009，69（20）：8067-8075.
[19] Murakami S. Soluble interleukin-2 receptor in cancer [J]. Front Biosci，2004，9（9）：3085-3090.
[20] Ma CS，Suryani S，Avery DT，et al. Early commitment of na?觙ve human CD4+ T cells to the T follicular helper TFH cell lineage is induced by IL-12 [J]. Immunol Cell Biol，2009，87（8）：590-600.
[21] Fu J，Xu D，Liu Z，et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients [J]. Gastroenterology，2007，132（7）：2328-2339.
[22] Bergmann C，Wild CA，Narwan M，et al. Human tumor-induced and naturally occurring Treg cells differentially affect NK cells activated by either IL-2 or target cells [J]. Eur J Immunol，2011，41（12）：3564-3573.
[23] Ghiringhelli F，Ménard C，Martin F，et al. The role of regulatory T cells in the control of natural killer cells：relevance during tumor progression [J]. Immunol Rev，2006， 214（12）：229-238.
[24] Zhang JP，Yan J，Xu J，et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients [J]. J Hepatol，2009，50（5）：980-989.
[25] Murugaiyan G，Saha B. Protumor vs antitumor functions of IL-17 [J]. J Immunol，2009，183（7）：4169-4175.
[26] Yan J，Liu XL，Xiao G，et al. Prevalence and clinical relevance of T-helper cells，Th17 and Th1，in hepatitis B virus-related hepatocellular carcinoma [J]. PLoS One，2014，9（5）：e96080.
[27] Berzofsky JA，Terabe M. The contrasting roles of NKT cells in tumor immunity [J]. Curr Mol Med，2009，9（6）：667-672.
[28] Bricard G，Cesson V，Devevre E，et al. Enrichment of human CD4+ Vα24/Vβ11 invariant NKT cells in intrahepatic malignant tumors [J]. J Immunol，2009，182（8）：5140-5151.
[29] Anson M，Crain-Denoyelle AM，Baud V，et al. Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice [J]. J Clin Invest，2012，122（2）：586-599. |
|
|
|
